Vertex Pharmaceuticals Incorporated (VRTX) price prediction
We do not issue point price predictions. Instead, our analysis anchors VRTX to a composite fair-value range of $428–$722 (midpoint $574, current price $430) and a probability-weighted bull/base/bear distribution that resolves to a weighted price target of $574.46 and a weighted return of +33.7%.
Bull, base and bear price targets
Bull case (probability 20%): target $721.50, implied return +67.9%. Base case (probability 60%): target $574.46, implied return +33.7%. Bear case (probability 20%): target $428.44, implied return -0.3%.
These are not points-on-a-chart guesses. Each scenario is built from explicit revenue, margin, and capital-allocation assumptions, and discounted at 6.95%. Probability weights are calibrated to Vertex Pharmaceuticals Incorporated's mature compounder archetype — the bull tail is fatter for hyper-growth names, thinner for mature compounders, and inverted for cyclicals near peak.
Probability-weighted expected return
Folding bull/base/bear into a single weighted view, VRTX's probability-weighted price target is $574.46 and the weighted return is +33.7%. The asymmetry signal — the gap between weighted return and base-case return — is Probability-weighted scenario value points to favorable asymmetry versus the current price across the bear, base, and bull paths..
Asymmetry matters more than the headline return. A 10% expected return with a 30%-bear/15%-bull dispersion is a different bet than a 10% expected return with a 10%-bear/12%-bull dispersion. The full report walks through both for VRTX.
What our forecast deliberately does not do
We do not publish twelve monthly price targets across a calendar year, we do not back-test indicators on past prices, and we do not anchor any number to "analyst consensus" — the consensus is a useful sanity check, not a target. If our composite fair value differs from the analyst consensus by more than 30%, the full report runs a consensus-divergence diagnostic instead of silently revising toward the crowd.
What we do publish: the 5×5 Ke-versus-terminal-growth sensitivity matrix, five formal stress tests with quantified fair-value impact, an earnings decision tree if reporting is within 60 days, and explicit position-management checkpoints. Together those answer "what if my view is wrong?" — a more useful question for an investor than "what's the price next month?".
How to use this for VRTX
Anchor on the fair-value range ($428–$722), size against the bull/base/bear distribution, and define a kill-scenario list before entry. Our current rating for VRTX is Strong Buy; rating-band changes are the trigger for re-sizing, not for trading the noise around them.
For the canonical version of this answer — including the sensitivity matrix, scorecard, and full assumption ledger — see the full report at /stocks/vrtx/analysis.
Frequently asked questions
What is the price prediction for VRTX?
We anchor VRTX to a fair-value range of $428–$722, with a midpoint of $574. The probability-weighted price target is $574.46 (weighted return +33.7%). We do not issue single-point price predictions.
What is the bull-case target for VRTX?
The bull case (probability 20%) targets $721.50, an implied return of +67.9%.
What is the bear-case target for VRTX?
The bear case (probability 20%) targets $428.44, an implied return of -0.3%.
Do you publish a 12-month VRTX price target?
No. We publish a fair-value range, a bull/base/bear distribution with explicit probabilities, and a probability-weighted expected return — not a single 12-month point.
Research for educational purposes. Not personalised investment advice. See the full VRTX report for the canonical evidence.